BRIEF—Seattle Genetics lifts lid on ASCO 2019 data

Seattle Genetics will present data from six of its programs at the American Society of Clinical Oncology (ASCO) annual meeting later this month.

Chief medical officer Roger Dansey said: “Data to be presented on our approved or investigational targeted medicines support our efforts toward becoming a multi-product oncology company.”

“Importantly, the oral presentation of the results from the EV-201 pivotal trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer is our first solid tumor late-stage development program.”

“We are also presenting updated analyses from the ECHELON-1 and ECHELON-2 frontline Phase III trials of Adcetris (brentuximab vedotin) that is approved for several types of lymphomas.”